

Date: August 26, 2022

Administrative Circular: 2022:35

ATTN: Medical Health Officers and Branch Offices Public Health Nursing Administrators and Assistant Administrators Holders of Communicable Disease Control Manuals

Re: Update to Communicable Disease Control Manual, Chapter 2: Immunization, Part 4 – Biological Products & Appendix E – Management of Biologicals

Part 4 – Biological Products

COVID-19 Vaccines

COVID-19 Vaccine Eligibility

• The eligibility table has been updated to include the booster dose for individuals 5-11 years of age.

Please remove page numbers: 1-3 dated July 22, 2022 Please add new page numbers: 1-3 dated August 26, 2022

COVID-19 Vaccine COMIRNATY® (Pfizer-BioNTech) Pediatric (Orange Vial Cap)

- **Doses and Schedule**: The dose and schedule for the booster dose has been added.
- **Booster Doses**: The previous content stating that booster doses are not recommended has been revised to indicate that a booster dose is recommended at least 6 months after the primary series has been completed for individuals 5-11 years of age.

Please remove page numbers: 1-5 dated July 29, 2022 Please add new page numbers: 1-5 dated August 26, 2022

Monkeypox Vaccine


Smallpox and Monkeypox Vaccine (Live attenuated, non-replicating): IMVAMUNE®

- Administration: Storage and Handling has been updated as follows:
 - Content indicating that the vaccine will be shipped to health authorities at +2°C to +8°C refrigerator conditions for immediate use has been removed.

Page 1 of 3







• The expiry date information for vaccine stored at -25°C to -15°C has been revised to indicate that any time used for transport of the vaccine at -20°C is cumulative and needs to be subtracted from the allowable storage time at -25°C to -15°C.

Please remove page numbers: 1-4 dated August 8, 2022 Please add new page numbers: 1-4 dated August 26, 2022

The <u>Monkeypox Vaccine Client Information Sheet</u> has been updated to indicate that the vaccine is given as one dose, however people who are moderately to severely immunocompromised should get 2 doses, 4 weeks apart.

Appendix E – Management of Biologicals

BC Centre for Disease Control

Provincial Health Services Authority

<u>Guidance for Receiving and Handling the Pfizer-BioNTech COVID-19 mRNA Vaccine</u> (including dry ice procedures)

• The heading on page 3 for the Orange Vial Cap and Label Border has been revised to "(for those 5-11 years of age inclusive)".

Please remove page number: 3 dated July 29, 2022 Please add new page number: 3 dated August 26, 2022





BC Centre for Disease Control Provincial Health Services Authority

If you have any questions or concerns, please contact Stephanie Meier, Senior Practice Leader, BCCDC (telephone: 604-707-2577 / email: <u>stephanie.meier@bccdc.ca</u>).

Sincerely,

deitre brans

Monika Naus MD MHSc FRCPC FACPM Medical Director Communicable Diseases & Immunization Service BC Centre for Disease Control

pc:

Provincial Health Officer Dr. Bonnie Henry

Dr. Reka Gustafson Vice President, Public Health & Wellness, PHSA & Deputy Provincial Health Officer

Deputy Provincial Health Officer Dr. Martin Lavoie BC Ministry of Health, Population & Public Health Division:

Brian Sagar Senior Director Communicable Disease, Population and Public Health Division

Bernard Achampong Executive Director, Public Health, Planning and Prevention, Population and Public Health Division



